Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan 3, 2023--
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of management will present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023. The presentation will begin at 10:30 A.M. Pacific Time (1:30 P.M. Eastern Time).
To access a live webcast of the presentation, visit Teva’s Investor Relations website at http://ir.tevapharm.com/.
An archived version of the webcast will be available within 24 hours after the end of the live discussion and will be accessible for up to 30 days.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our substantial indebtedness; our business and operations in general including: uncertainty regarding the COVID-19 pandemic and the governmental and societal responses thereto; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Rerport on Form 10-Q for the third quarter of 2022 and in our Annual Report on Form 10-K for the year ended December 31, 2021, including in the sections captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230103005134/en/
CONTACT: IR ContactsRan Meir
(267) 468-4475Yael Ashman
+972 (3) 914 8262PR ContactsKelley Dougherty
(973) 832-2810Eden Klein
+972 (3) 906 2645
KEYWORD: NEW JERSEY UNITED STATES NORTH AMERICA ISRAEL MIDDLE EAST
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Teva Pharmaceutical Industries Limited
Copyright Business Wire 2023.
PUB: 01/03/2023 04:30 PM/DISC: 01/03/2023 04:30 PM